Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas

British Journal of Neurosurgery

Volumn 29, Issue 4, 2015, Pages 524-531

  Pavlov, Vladislav ^a,b   Page, Philippe ^a,b   Abi Lahoud, Georges ^a,b   Nataf, François ^a,b   Dezamis, Edouard ^a,b   Robin, Audrey ^a   Varlet, Pascale ^a,b   Turak, Baris ^a,b   Dhermain, Frédéric ^c   Domont, Julien ^c   Louvel, Guillaume ^c   Souillard Scemama, Raphälle ^a,b   Parraga, Eduardo ^a,b   Meder, Jean François ^a,b   Chrétien, Fabrice ^a,b   Devaux, Bertrand ^a,b   Pallud, Johan ^a,b  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

carmustine wafers; glioblastoma; Stupp regimen; survival

Indexed keywords

BEVACIZUMAB; CARMUSTINE; GADOLINIUM PENTETATE MEGLUMINE; IRINOTECAN; TEMOZOLOMIDE; ALKYLATING AGENT;

ABSCESS; ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DYING; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOSARCOMA; HEMATOMA; HISTOPATHOLOGY; HUMAN; INTRAOPERATIVE PERIOD; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYELONEPHRITIS; RADIATION INJURY; RETROSPECTIVE STUDY; STUPP REGIMEN; SURGICAL INFECTION; UNSPECIFIED SIDE EFFECT; CLINICAL PROTOCOL; MIDDLE AGED; OUTCOME ASSESSMENT; PEROPERATIVE CARE; PROCEDURES; SUPRATENTORIAL NEOPLASMS; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC PROTOCOLS; CARMUSTINE; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SUPRATENTORIAL NEOPLASMS; YOUNG ADULT;

EID: 84940758615     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2015.1012051     Document Type: Article

References (30)

1. Preusser M, de Ribaupierre S, Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011;70:9-21.
2. Pallud J, Dezamis E, Audureau E, et al. Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis. J Neurosurg 2012;117:476-85.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
4. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
5. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-12.
6. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5:79-88.
7. Duntze J, Litré CF, Eap C, et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol 2013;20:2065-72.
8. Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 2008;88:353-7.
9. Affronti ML, Heery CR, Herndon JE 2nd, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115:3501-11.
10. Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010;33:441-9.
11. Mc Gir t MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583-8.
12. Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 2010;17:1740-6.
13. La Rocca R, Hodes J, Villanueva W, et al. (2006). A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion. Abstract presented at the Annual Meeting of the Society of Neuro-oncology, Orlando, FL (Abstract).
14. Salmaggi A, Milanesi I, Silvani A, et al. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. J Neurosurg 2013;118:821-9.
15. Barr JG, Grundy PL. The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma. Br J Neurosurg 2012;26:818-22.
16. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
17. Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563-9.
18. Berger MS, Tucker A, Spence A, Winn HR. Reoperation for glioma. Clin Neurosurg 1992;39:172-86.
19. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3-8.
20. Cancer Therapy Evaluation Program (2006). Common terminology criteria for adverse events. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf (Accessed 27 April 2013).
21. Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70:234-43.
22. Gallego JM, Barcia JA, Barcia-Mariño C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir (Wien) 2007;149:261-5.
23. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997;41:44-8.
24. Miglierini P, Bouchekoua M, Rousseau B, et al. Impact of the peroperatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin Neurol Neurosurg 2012;114:1222-5.
25. Noël G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 2012;82:749-55.
26. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009;110:156-62.
27. Darlix A, Baumann C, Lorgis V, et al. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res 2013;33:3467-74.
28. De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. Acta Neurochir (Wien) 2012;154:1371-8.
29. Metellus P, Coulibaly B, Nanni I, et al. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 2009;115:4783-94.
30. Lechapt-Zalcman E, Levallet G, Dugué AE, et al. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 2012;118:4545-54.